Who are Molgramostim Open-label's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/molgramostim-open-label.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Molgramostim Open-label — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Molgramostim Open-label (Molgramostim Open-label) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cytokine; GM-CSF receptor agonist. Area: Immunology; Rare/Orphan Diseases.

phase 3 Cytokine; GM-CSF receptor agonist GM-CSF receptor (CD116/CD131) Immunology; Rare/Orphan Diseases Small molecule Live · refreshed every 30 min

Target snapshot

Molgramostim Open-label (Molgramostim Open-label) — Savara Inc.. Molgramostim is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) that stimulates the production and activation of granulocytes and macrophages to enhance immune function.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Molgramostim Open-label TARGET	Molgramostim Open-label	Savara Inc.	phase 3	Cytokine; GM-CSF receptor agonist	GM-CSF receptor (CD116/CD131)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cytokine; GM-CSF receptor agonist class)

Savara Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Molgramostim Open-label — Competitive Intelligence Brief. https://druglandscape.com/ci/molgramostim-open-label. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing